deaths (OS)

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
avelumab plus axitinib vs. sunitinib 1 0.69 [0.58; 0.83], 1 RCT, I2=0%
unassessable degree of certainty